Showing papers by "Betty Soliven published in 2006"
TL;DR: The identical PLN mutation can be associated with both mild and severe forms of dilated cardiomyopathy, and PLN mutations should be considered in late onset cardiomeopathy.
80 citations
TL;DR: It is shown that hyrt mutant mice have much lower levels of γ-aminobutyric acid type A (GABAA) receptors in their CNS, particularly the lower motor neurons, than do wild-type mice, indicating that the hypertonicity of the mutants is likely to be caused by deficits in GABA-mediated motor neuron inhibition.
Abstract: Hypertonia, which results from motor pathway defects in the central nervous system (CNS), is observed in numerous neurological conditions, including cerebral palsy, stroke, spinal cord injury, stiff-person syndrome, spastic paraplegia, dystonia and Parkinson disease. Mice with mutation in the hypertonic (hyrt) gene exhibit severe hypertonia as their primary symptom. Here we show that hyrt mutant mice have much lower levels of γ-aminobutyric acid type A (GABAA) receptors in their CNS, particularly the lower motor neurons, than do wild-type mice, indicating that the hypertonicity of the mutants is likely to be caused by deficits in GABA-mediated motor neuron inhibition. We cloned the responsible gene, trafficking protein, kinesin binding 1 (Trak1), and showed that its protein product interacts with GABAA receptors. Our data implicate Trak1 as a crucial regulator of GABAA receptor homeostasis and underscore the importance of hyrt mice as a model for studying the molecular etiology of hypertonia associated with human neurological diseases.
62 citations
TL;DR: When CNS and PNS demyelinating diseases occur concurrently, effective treatment for CNS disease can be safely combined witheffective treatment for PNS disease.
Abstract: Inflammatory demyelinating diseases comprise a spectrum of disorders that affect central nervous system (CNS) and peripheral nervous system (PNS) myelin. Most individuals have demyelinating disease restricted to one or the other compartment but patients with concomitant CNS and PNS inflammatory inflammatory demyelinating processes have been reported not infrequently. In most such patients, involvement of either the CNS or the PNS predominates the clinical picture. Involvement of the other compartment is usually mild or subclinical with unclear prognostic and therapeutic implications. Similarly, while experimentally induced demyelinating disease in animal models is usually CNS or PNS predominant, varying degrees of pathology in the other system can occur depending on the species, type of immunogen, and genetic background of the immunized animal. When CNS and PNS demyelinating diseases occur concurrently, effective treatment for CNS disease can be safely combined with effective treatment for PNS disease.
6 citations
TL;DR: The name of the fourth author has now been included in the author list.
Abstract: Nat. Genet. 38, 245–250 (2005). The name of the fourth author has now been included in the author list. Jeffrey R. Anderson is at the Howard Hughes Medical Institute and Department of Human Genetics, University of Chicago, Chicago, Illinois 60637, USA.
2 citations